Laura Brege Biography and Net Worth

Director of ACADIA Pharmaceuticals

Ms. Brege is Managing Director of Cervantes Life Science Partners, LLC., a healthcare advisory and consulting company. Prior to joining Cervantes Life Science Partners from September 2012 to July 2015, Ms. Brege served as Chief Executive Officer and President of Nodality, Inc., a privately held biotechnology company focused on oncology and immunology.

Previously, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc. from June 2006 to December 2011, including Executive Vice President and Chief Operating Officer. Before joining Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early stage financing for technology companies. Prior to Red Rock, she was Senior Vice President and Chief Financial Officer at COR Therapeutics. Earlier in her career, Ms. Brege served as Vice President and Chief Financial Officer at Flextronics and Vice President and Treasurer of The Cooper Companies.

Ms. Brege serves on the boards of Dynavax Technologies Corporation, HLS Therapeutics Inc., Pacira BioSciences, Inc., and Portola Pharmaceuticals, Inc. Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago.

What is Laura Brege's net worth?: The estimated net worth of Laura Brege is at least $354.86 thousand as of September 11th, 2025. Ms. Brege owns 15,703 shares of ACADIA Pharmaceuticals stock worth more than $354,856 as of May 8th. This net worth estimate does not reflect any other investments that Ms. Brege may own. Learn More about Laura Brege's net worth.
How do I contact Laura Brege?: The corporate mailing address for Ms. Brege and other ACADIA Pharmaceuticals executives is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. ACADIA Pharmaceuticals can also be reached via phone at (858) 558-2871 and via email at [email protected]. Learn More on Laura Brege's contact information.
Has Laura Brege been buying or selling shares of ACADIA Pharmaceuticals?: Laura Brege has not been actively trading shares of ACADIA Pharmaceuticals during the last quarter. Most recently, Laura Brege sold 14,446 shares of the business's stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $21.78, for a transaction totalling $314,633.88. Following the completion of the sale, the director now directly owns 15,095 shares of the company's stock, valued at $328,769.10. Learn More on Laura Brege's trading history.
Who are ACADIA Pharmaceuticals' active insiders?: ACADIA Pharmaceuticals' insider roster includes Laura Brege (Director), James Daly (Director), Stephen Davis (CEO), Elizabeth Garofalo (Director), James Kihara (Insider), Austin Kim (EVP), Jennifer Rhodes (Chief Legal Officer and Secretary), Elena Ridloff (CFO), Mark Schneyer (CFO), Srdjan Stankovic (President), and Brendan Teehan (COO). Learn More on ACADIA Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ACADIA Pharmaceuticals?: During the last year, insiders at the biopharmaceutical company sold shares 14 times. They sold a total of 107,417 shares worth more than $2,494,763.14. The most recent insider tranaction occured on May, 4th when insider James Kihara sold 1,332 shares worth more than $29,024.28. Insiders at ACADIA Pharmaceuticals own 26.2% of the company. Learn More about insider trades at ACADIA Pharmaceuticals.
Information on this page was last updated on 5/4/2026.

Laura Brege Insider Trading History at ACADIA Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/4/2025	Sell	14,446	$21.78	$314,633.88	15,095
6/12/2023	Sell	4,500	$24.87	$111,915.00	13,502
1/12/2023	Sell	12,500	$18.25	$228,125.00
1/7/2020	Sell	10,000	$42.19	$421,900.00	10,000
1/9/2019	Sell	10,000	$20.00	$200,000.00	10,000
1/2/2018	Sell	25,000	$30.06	$751,500.00	15,000
9/15/2014	Sell	10,000	$28.07	$280,700.00
10/10/2013	Sell	10,000	$21.63	$216,300.00
9/10/2013	Sell	46,153	$22.80	$1,052,288.40

Laura Brege Buying and Selling Activity at ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Company Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Today's Range

Now: $22.60

$22.33

$22.91

50 Day Range

MA: $22.06

$20.32

$25.05

2 Week Range

Now: $22.60

$16.76

$28.35

Volume

700,922 shs

Average Volume

1,710,345 shs

Market Capitalization

$3.87 billion

P/E Ratio

10.30

Dividend Yield

N/A

Beta

0.86